Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
EWTXBOULDER, Colo., Jan. 6, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Kevin Koch, Ph.D., President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference....
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
EWTX(NASDAQ:EWTX) BOULDER, Colo., Sept. 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on August...
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
EWTXBOULDER, Colo., Aug. 6, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on July...
RBC Capital Reiterates Outperform on Edgewise Therapeutics, Maintains $48 Price Target
EWTXEdgewise Therapeutics Q1 EPS $(0.43), Inline
EWTXWedbush Maintains Outperform on Edgewise Therapeutics, Maintains $43 Price Target
EWTXRBC Capital Maintains Outperform on Edgewise Therapeutics, Lowers Price Target to $52
EWTXScotiabank Downgrades Edgewise Therapeutics to Sector Perform, Lowers Price Target to $14
EWTXPiper Sandler Maintains Overweight on Edgewise Therapeutics, Maintains $51 Price Target
EWTXEdgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study
EWTXEdgewise's EDG-7500 lowered LVOT gradient and NT-proBNP levels in HCM patients, improving symptoms. Initial Part D data is expected in late 2025.
Why Edgewise Therapeutics (EWTX) Stock Is Falling
EWTXEdgewise Therapeutics shares are trading lower by 25.7% during Wednesday's session. The company announced an approximate $200 million offering.
Edgewise Therapeutics Priced An Underwritten Offering Of 9.94M Shares At $20.13 Per Share. Edgewise Anticipates Gross Proceeds From The Offering To Be Approximately $200M
EWTXEdgewise Therapeutics Announced Topline Data Of EDG-7500 From The Phase 2 CIRRUS-HCM Four-week Trial In Participants With Obstructive Or Nonobstructive Hypertrophic Cardiomyopathy
EWTXScotiabank Initiates Coverage On Edgewise Therapeutics with Sector Outperform Rating, Announces Price Target of $50
EWTXRBC Capital Reiterates Outperform on Edgewise Therapeutics, Maintains $56 Price Target
EWTXEdgewise Therapeutics Q4 EPS $(0.42) vs $(0.36) QoQ
EWTXEdgewise Therapeutics Announces 2025 Priorities, Progress In Muscular Dystrophy And Cardiac Therapies; Seeks Completion Of GRAND CANYON Recruitment For Becker Trials In Q1; Targets Phase 2 FDA Feedback On CANYON In H1; Plans Phase 3 For Duchenne
EWTXEdgewise Therapeutics Announces Proposed $100M Offering Of Common Stock
EWTXEdgewise Therapeutics Announced 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy; Announced Significant Decrease in Levels of Serum Creatine Kinase and Fast Skeletal Muscle Troponin I
EWTX